Vaccinex Reports New Glial Biomarker Data for Pepinemab, Outlines Path to Expanded Phase 2b Alzheimer’s Study 4 months ago AnaIn Deals
Beyond Amyloid: AAIC 2026 Signals a Broader, More Testable Alzheimer’s Pipeline 4 months ago AnaIn Clinical TrialsFeatured AnalysisIndustry ConferencesResearch Updates
Celea Therapeutics Launches With $180 Million to Challenge Pirfenidone in IPF 4 months ago AnaIn DealsFunding RoundsResearch UpdatesStartups
TGA Clears Sanofi’s Once-Weekly Haemophilia A Therapy for Australian Market 4 months ago AnaIn BreakthroughsResearch Updates
Epcoritamab Clears Phase 3 Bar in Relapsed Large B-Cell Lymphoma 4 months ago AnaIn Clinical TrialsPartnershipsResearch Updates
Vertex’s Casgevy Clears FDA Hurdle for Youngest Sickle Cell Patients 4 months ago AnaIn Breaking NewsBreakthroughsFDA ApprovalsPartnerships
No Single Mechanism Solves Epilepsy: What Bright Minds’ BMB-101 Data Tells Us About the Future of Seizure Control 4 months ago AnaIn AI & DataFeatured AnalysisLeadersPeopleResearch Updates
TGA Clears Sanofi’s Once-Weekly Haemophilia A Therapy Altuviiio, Widening Treatment Options for Australian Patients 4 months ago AnaIn BreakthroughsClinical TrialsPharma Industry UpdatesTop Stories
Slate Medicines Emerges With $130 Million to Chase PACAP, a Migraine Target Distinct From CGRP 4 months ago AnaIn DealsFunding RoundsInnovationInvestments
FDA Extends Casgevy’s Reach to Children as Young as Two, Reshaping the Sickle Cell Treatment Landscape 4 months ago AnaIn Breaking NewsFDA ApprovalsInnovationPharma Industry Updates
Orca Bio’s Tregzi Wins FDA Approval as First Regulatory T-Cell Therapy to Curb Chronic Graft-Versus-Host Disease 4 months ago AnaIn BreakthroughsFDA ApprovalsFeatured AnalysisResearch Updates
Epcoritamab Combination Hits Progression-Free Survival Mark in Phase 3 Lymphoma Trial, Genmab and AbbVie Report 4 months ago AnaIn BreakthroughsClinical TrialsPartnershipsResearch Updates
Biotech M&A Surpasses $106 Billion in 2026 as Big Pharma Races to Replenish Pipelines Before Patent Cliffs 5 months ago AnaIn DealsFunding RoundsInvestmentsPartnerships
Gilead’s Bictegravir/Lenacapavir Combination Wins FDA Priority Review, PDUFA Date Set for August 2026 5 months ago AnaIn FDA ApprovalsResearch UpdatesTop Stories
Definium’s DT120 Delivers Rapid, Durable Antidepressant Effect in Phase 3 EMERGE Trial — LSD Analogue Posts Landmark MDD Results 5 months ago AnaIn Breaking NewsClinical TrialsFeatured AnalysisResearch Updates
